Aspen Pharmacare CEO Stephen Saad has hailed the group’s licensing agreement to enter the rapidly expanding GLP-1 agonist market, deeming it “a coup”.
With preparations under way to ensure readiness for the GLP-1 market by 2026, the agreement positions Aspen to tap into a lucrative sector driven by increasing global demand for diabetes and obesity solutions, with the market projected to expand to over $142bn (R2.5-trillion) by 2030...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.